Drug intelligence / Profile preview

D1ME100

Development stage: Phase 1
Lead developer: Naval Medical Research Center
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

D1ME100 is a monovalent DNA plasmid vaccine developed for dengue prevention, specifically targeting dengue serotype 1 (DENV-1). It contains the genetic material (prM and approximately 92% of the envelope (E) genes) from DENV-1, which directs host cells to produce viral proteins. When administered, the vaccine is designed to induce both humoral (antibody-mediated) and cellular immunity against the dengue virus.

Targets

DENV-1 antigens (Dengue virus serotype 1 antigens)

Beyond the preview

Go deeper on D1ME100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D1ME100.

Explore the full profile